Insight Molecular
IMDX
Insight Molecular (IMDX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.23
- EPS estimate
- −$0.24
- EPS surprise
- +4.17%
- Revenue surprise
- −45.37%
- Revenue
- $239,000.00
- Revenue estimate
- $437,500.00
- Reported
- Aug 10, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 10, 2026 | −$0.24 | −$0.23 | +4.17% | $239,000.00 | SEC |
| Q1 2026 | May 13, 2026 | −$0.26 | −$0.28 | −7.07% | $32,000.00 | SEC |
| Q4 2025 | Mar 26, 2026 | −$0.24 | −$0.27 | −13.68% | $1.1M | SEC |
| Q3 2025 | Nov 10, 2025 | −$0.21 | −$0.20 | +4.71% | $260,000.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.23 | −$0.30 | −30.43% | $518,000.00 | SEC |
| Q1 2025 | May 12, 2025 | −$0.24 | −$0.26 | −9.47% | $2.1M | SEC |
| Q4 2024 | Mar 24, 2025 | −$0.40 | −$1.93 | −382.50% | $1.5M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.44 | −$0.40 | +7.99% | $115,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.56 | −$0.38 | +31.29% | $104,000.00 | SEC |
| Q1 2024 | May 15, 2024 | −$0.67 | −$0.62 | +7.81% | $176,000.00 | SEC |
| Q4 2023 | Apr 12, 2024 | −$0.70 | −$2.27 | −224.29% | $314,000.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$1.01 | −$0.81 | +19.67% | $429,000.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$1.30 | −$1.07 | +17.53% | $463,000.00 | SEC |
| Q1 2023 | May 11, 2023 | −$1.80 | $0.40 | +122.22% | $297,000.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$2.27 | −$1.69 | +25.34% | $1.0M | — |
| Q2 2022 | Aug 10, 2022 | −$2.40 | −$1.40 | +41.67% | $2.1M | — |
| Q1 2022 | May 11, 2022 | −$2.43 | −$2.20 | +9.41% | $1.4M | — |
| Q4 2021 | Mar 10, 2022 | −$2.46 | −$7.80 | −217.45% | $3.6M | — |
| Q3 2021 | Nov 9, 2021 | −$2.30 | −$3.00 | −30.41% | $984,000.00 | — |
| Q2 2021 | Aug 10, 2021 | −$2.01 | −$2.40 | −19.34% | $2.0M | — |
Quarterly revenue
Frequently asked questions
When did Insight Molecular (IMDX) last report earnings?
Insight Molecular last reported on Aug 10, 2026, covering fiscal Q2 2026.
Did IMDX beat earnings estimates?
Yes. Insight Molecular reported EPS of −$0.23 for Q2 2026 against a −$0.24 estimate — a 4.17% beat.
How much revenue did IMDX report last quarter?
Insight Molecular reported $239,000.00 in revenue for Q2 2026, against a consensus estimate of $437,500.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.